The MSO Uplisting Question: Why Nobody Agrees, and What's Actually True
Zero US plant-touching MSOs trade on NYSE or NASDAQ — and SAFE Banking, the April 2026 partial rescheduling, and Trulieve's Delaware move don't change that on their own. A deep dive into where MSOs actually trade, the NASDAQ Rule 5101 wall, the MSOS swap book held together by five non-US-bank counterparties, and the three-layered stack of events (broader rescheduling + CLIMB-style safe harbor + exchange policy revision) that has to clear before the first uplisting. Base case: late 2027 to mid-2028.
The Quiet Substitution: Why the People Who Actually Switched From Beer to THC Are Switching All the Way
Gallup's 2025 poll says only 54% of Americans drink alcohol — the lowest in 90 years of tracking. But the analysts buried the substitution story: at the population level, cannabis isn't the reason. At the cohort level, it absolutely is. People who started drinking THC seltzers cut their alcohol intake from 7.02 to 3.35 drinks per week. Inside the averages, a generational substitution is happening — and wine, craft beer, and bars are losing.
Green Thumb Is Paying $70 Million a Year to License Its Own Brands
Green Thumb's Q1 looks clean by cannabis standards: $300M revenue up 7.4% YoY, $76M operating cash flow, $54.6M net cash, an aggressive buyback. But starting Q2, GTI begins paying $70 million a year in fixed brand-licensing fees to RYTHM, Inc. — a separately Nasdaq-listed holding company chaired by GTI's own CEO. The $15.4M net income was flattered by a $17M Ascend arbitration win and $6.5M RYTHM equity income; strip those out and operating income actually declined year-over-year. The DEA registration filing, the Texas TCUP license, and the dual-entity architecture all telegraph one thing: Green Thumb is engineering itself into something that isn't quite a cannabis operator anymore.
The $99 Million Line Item Curaleaf Doesn't Want You to Overthink
Curaleaf's $70M Q1 profit was a 280E reversal in disguise — strip out the $98.7M one-time tax benefit and pre-tax operating losses actually widened 74% year-over-year. The headline beat masks compressing margins, a 1.3% FCF margin, and an 11.5% bond coupon. The real story is structural: a BDO auditor swap, DEA registration filings, the completed Four 20 Pharma consolidation, and a quiet domestic wholesale pivot. Curaleaf is methodically rebuilding its infrastructure for a major-exchange uplisting.
Verano Q1 2026: The First MSO Read-Through Post Schedule III
Verano's $208M quarter looks flat on the surface — but it landed eight days after Acting AG Blanche moved state-licensed medical cannabis to Schedule III, structurally erasing 280E for ~60% of retail revenue. With the cheapest valuation in the Tier 1 group, a fresh $20M buyback, a $195M senior secured term loan, and a completed Nevada redomicile, Verano comes into the June 29 DEA hearing as the cleanest re-rate vehicle on the board.
The road to Schedule III
Tracking every step of the federal rescheduling process — from Biden's 2022 review order through Trump's executive action and the April 23 DOJ order moving medical cannabis to Schedule III, to the June 29 Phase Two hearing on full rescheduling.
Six a.m. Eastern. Before the market opens.
One email. The night's moves, the morning's agenda, and three things every operator needs to know before 9:30.